Type: Press Release
… $1856 million an increase of 8% compared to revenue of $1726 million during the same period of fiscal 2019 with US … published FDA-audited peer-reviewed real-world studies and randomized controlled trials The totality of the … and animations is available on the investor section of our website “Abiomed remains steadfast on our goal of creating …
Type: Press Release
… or 292% operating margin compared to $467 million or 260% operating margin in the same period of fiscal 2019 GAAP … has been endorsed by SCAI and resides on the SCAI website at http//wwwscaiorg/vascular-access-and-closure On … enrollment criteria of Impella RP’s premarket clinical studies The letter reiterated that the Impella RP heart pump is …
Type: Press Release
… New research adds to 12 years of real-world data and FDA studies demonstrating the use of Abiomeds (NASDAQ ABMD) Impella … skilled interventional cardiologists to achieve more complete revascularization improved ejection fraction and … had a 31% improvement in LVEF at 30 day follow up (from 26 ± 6% to 34 ± 11% p = 0003) Circulation 2012 -The PROTECT …
Type: Press Release
… fiscal 2018 revenue of $1540 million an increase of 34% compared to revenue of $1147 million for the same period of … year guidance for GAAP operating margin to approximately 26% This compares to the Companys prior fiscal 2018 … 8024 Total current assets 422198 326958 Long-term marketable securities 49485 …
Type: Press Release
… second quarter fiscal 2013 revenue of $374 million up 27% compared to revenue of $295 million in the same period of … an increase of $118 million from March 31 2012 On October 26 2012 Abiomed was informed that the United States … current assets 124034 110539 Property and equipment net 6268 6378 Intangible assets net -- 115 Goodwill 35512 …
Type: Press Release
… fiscal 2020 revenue of $2050 million an increase of 13% compared to revenue of $1818 million for the same period of … via axillary artery or direct to the aorta On September 26 the company announced the results of PROTECT III the … 31727 32601 In-process research and development …
Type: Press Release
… 2021 revenue of $2098 million a sequential increase of 27% compared to Q1 fiscal year 2021 and a year over year … a sequential increase of 29% compared to revenue of $1262 million during Q1 fiscal year 2021 and a decrease of 1% … cardiogenic shock (AMICS) patients was presented in two studies The first study presented by Hemindermeet Singh MD of …
Type: Press Release
… record fourth quarter fiscal 2021 revenue of $2412 million compared to revenue of $2067 million for the same period of … for the fourth quarter fiscal 2021 was $628 million or 260% operating margin compared to $581 million or 281% … gain on our investment in Shockwave and $121 million or $026 per diluted share of excess tax benefits related to …
Type: Press Release
… for the quarter totaled $2481 million an increase of 18% compared to $2098 million during the same period of the … revenue for the quarter totaled $460 million an increase of 26% compared to $365 million during the same period of the … 85986 81059 Prepaid expenses and other current assets 45374 26032 Total current assets 871487 787965 Long-term …